Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 18;6(1):1058.
doi: 10.1038/s42003-023-05317-9.

Calpeptin is a potent cathepsin inhibitor and drug candidate for SARS-CoV-2 infections

Patrick Y A Reinke #  1 , Edmarcia Elisa de Souza #  2 , Sebastian Günther #  1 , Sven Falke  1 , Julia Lieske  1 , Wiebke Ewert  1 , Jure Loboda  3   4 , Alexander Herrmann  5 , Aida Rahmani Mashhour  1 , Katarina Karničar  3   6 , Aleksandra Usenik  3   6 , Nataša Lindič  3 , Andreja Sekirnik  3 , Viviane Fongaro Botosso  7 , Gláucia Maria Machado Santelli  8 , Josana Kapronezai  7 , Marcelo Valdemir de Araújo  7   9 , Taiana Tainá Silva-Pereira  9   10 , Antônio Francisco de Souza Filho  9 , Mariana Silva Tavares  9 , Lizdany Flórez-Álvarez  2 , Danielle Bruna Leal de Oliveira  9 , Edison Luiz Durigon  9 , Paula Roberta Giaretta  11 , Marcos Bryan Heinemann  10 , Maurice Hauser  12 , Brandon Seychell  13 , Hendrik Böhler  13 , Wioletta Rut  14 , Marcin Drag  14 , Tobias Beck  13   15 , Russell Cox  12 , Henry N Chapman  1   15   16 , Christian Betzel  15   17 , Wolfgang Brehm  1 , Winfried Hinrichs  18 , Gregor Ebert  5   19 , Sharissa L Latham  20   21 , Ana Marcia de Sá Guimarães  9 , Dusan Turk  22   23 , Carsten Wrenger  24 , Alke Meents  25
Affiliations

Calpeptin is a potent cathepsin inhibitor and drug candidate for SARS-CoV-2 infections

Patrick Y A Reinke et al. Commun Biol. .

Abstract

Several drug screening campaigns identified Calpeptin as a drug candidate against SARS-CoV-2. Initially reported to target the viral main protease (Mpro), its moderate activity in Mpro inhibition assays hints at a second target. Indeed, we show that Calpeptin is an extremely potent cysteine cathepsin inhibitor, a finding additionally supported by X-ray crystallography. Cell infection assays proved Calpeptin's efficacy against SARS-CoV-2. Treatment of SARS-CoV-2-infected Golden Syrian hamsters with sulfonated Calpeptin at a dose of 1 mg/kg body weight reduces the viral load in the trachea. Despite a higher risk of side effects, an intrinsic advantage in targeting host proteins is their mutational stability in contrast to highly mutable viral targets. Here we show that the inhibition of cathepsins, a protein family of the host organism, by calpeptin is a promising approach for the treatment of SARS-CoV-2 and potentially other viral infections.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Cell entry pathways of SARS-CoV-2.
After initial virus binding with its S protein to the ACE2 receptor, cell entry proceeds via two pathways. In case of cell surface entry, the S-protein is cleaved by TMPRSS2, inducing membrane fusion and viral genome release. In case of the endosomal entry, the viral particle is internalized by clathrin-mediated endocytosis and subsequently the S-protein is activated by CatL in the endosome, followed by membrane fusion and genome release.
Fig. 2
Fig. 2. Inhibitor binding to the active site of CatL.
a Domain structure of CatL with Calpeptin derived from prodrug S-Calpeptin bound to the active site. b Close-up view of the active site of CatL with bound S-Calpeptin. Residues involved in the catalytic mechanism are highlighted in stick representation. c Surface representation of the empty active site of CatL with the catalytic cysteine highlighted in yellow. Calpeptin derived from S-Calpeptin (d) and the GC-376 aldehyde (e) bound to the CatL active site with highlighted subsites S1–S3.
Fig. 3
Fig. 3. Calpeptin and S-Calpeptin inhibit SARS-CoV-2 infection.
The viral titer (●) and the cell viability (♦) of VERO-CCL81 (a, b) and human LC-HK2 (c, d) cells were determined by RT-qPCR and CellTiter-Glo luminescence method, respectively. EC50 values for viral titers are shown. Individual data points and the mean (―) of three replicates of two biological experiments are displayed as line. EC50 was calculated by fitting the data using GraphPad Prism version 8.0.
Fig. 4
Fig. 4. Calpeptin and S-Calpeptin inhibit SARS-CoV-2 mediated CPE.
Calpeptin or S-Calpeptin were added to VERO-CCL81 at 2-fold serial dilutions (a, b) and to human LC-HK2 at 10-fold serial dilutions (c, d). CPE inhibition was determined via CellTiter-Glo® Luminescent Assay. EC50-values are shown. Individual data points (●) and the mean (―) of three replicates of two biological experiments for VERO-CCL81 cells (a, b) and LC-HK2 cells (c, d) are displayed. Compounds concentrations are presented in log scale for interpolation. EC50 was calculated by fitting the data using GraphPad Prism version 8.0.
Fig. 5
Fig. 5. S-Calpeptin treatment reduces viral load in trachea in a hamster SARS-CoV-2 infection model.
Golden Syrian hamsters were intranasally inoculated with SARS-CoV-2 on day 0. Daily treatment started on day 1 with 1 mg/kg S-Calpeptin subcutaneously (s.c.) and 1:100 DMSO (dimethyl sulfoxide) as control. Viral load was measured at day 3, 5, and 7 post infection in lungs and trachea. a SARS-CoV-2 RNA level expressed as viral RNA copies/copies of β-actin/g of tissue. b Infectious viral particles expressed as 50% tissue culture infective dose/g of tissue. n = 5 animals per group. Values are expressed in median, interquartiles and range. Statistically significant differences (p ≤ 0.05) were determined by two-sided Mann–Whitney U-test.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • SARS-CoV-2 Mpro responds to oxidation by forming disulfide and NOS/SONOS bonds.
    Reinke PYA, Schubert R, Oberthür D, Galchenkova M, Rahmani Mashhour A, Günther S, Chretien A, Round A, Seychell BC, Norton-Baker B, Kim C, Schmidt C, Koua FHM, Tolstikova A, Ewert W, Peña Murillo GE, Mills G, Kirkwood H, Brognaro H, Han H, Koliyadu J, Schulz J, Bielecki J, Lieske J, Maracke J, Knoska J, Lorenzen K, Brings L, Sikorski M, Kloos M, Vakili M, Vagovic P, Middendorf P, de Wijn R, Bean R, Letrun R, Han S, Falke S, Geng T, Sato T, Srinivasan V, Kim Y, Yefanov OM, Gelisio L, Beck T, Doré AS, Mancuso AP, Betzel C, Bajt S, Redecke L, Chapman HN, Meents A, Turk D, Hinrichs W, Lane TJ. Reinke PYA, et al. Nat Commun. 2024 May 7;15(1):3827. doi: 10.1038/s41467-024-48109-3. Nat Commun. 2024. PMID: 38714735 Free PMC article.
  • Structural Elucidation and Antiviral Activity of Covalent Cathepsin L Inhibitors.
    Falke S, Lieske J, Herrmann A, Loboda J, Karničar K, Günther S, Reinke PYA, Ewert W, Usenik A, Lindič N, Sekirnik A, Dretnik K, Tsuge H, Turk V, Chapman HN, Hinrichs W, Ebert G, Turk D, Meents A. Falke S, et al. J Med Chem. 2024 May 9;67(9):7048-7067. doi: 10.1021/acs.jmedchem.3c02351. Epub 2024 Apr 17. J Med Chem. 2024. PMID: 38630165 Free PMC article.
  • Cathepsin-Targeting SARS-CoV-2 Inhibitors: Design, Synthesis, and Biological Activity.
    Flury P, Breidenbach J, Krüger N, Voget R, Schäkel L, Si Y, Krasniqi V, Calistri S, Olfert M, Sylvester K, Rocha C, Ditzinger R, Rasch A, Pöhlmann S, Kronenberger T, Poso A, Rox K, Laufer SA, Müller CE, Gütschow M, Pillaiyar T. Flury P, et al. ACS Pharmacol Transl Sci. 2024 Jan 19;7(2):493-514. doi: 10.1021/acsptsci.3c00313. eCollection 2024 Feb 9. ACS Pharmacol Transl Sci. 2024. PMID: 38357286

References

    1. Sasaki M, et al. S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. Sci. Transl. Med. 2022;0:eabq4064. - PMC - PubMed
    1. Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature613, 558–564 (2022). - PMC - PubMed
    1. Hu, Y. et al. Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir. ACS Cent Sci. 24, 1658–1669 (2023). - PMC - PubMed
    1. Günther S, et al. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease. Science. 2021;372:642–646. - PMC - PubMed
    1. Mediouni S, et al. Identification of potent small molecule inhibitors of SARS-CoV-2 entry. SLAS Discov. 2022;27:8–19. - PMC - PubMed

Publication types